SMMT Summit Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Summit Therapeutics Inc reported revenue of n/a, net income of −$216M and diluted EPS of −$0.28; for the fiscal year ended December 2025 revenue was n/a.
SMMT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income n/a, net income −$1.08B (margin n/a), EPS −$1.44
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$226M, net income −$221M (margin n/a), EPS −$0.31
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$610M, net income −$615M (margin n/a), EPS −$0.99
- Fiscal year ended Dec 2022: revenue $705K, gross profit n/a, operating income −$72.1M, net income −$78.8M (margin -11174.8%), EPS −$0.41
- Fiscal year ended Dec 2021: revenue $1.81M, gross profit n/a, operating income −$86.2M, net income −$88.6M (margin -4897.8%), EPS −$0.67
SMMT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$216M, EPS −$0.28
- Quarter ended Mar 31, 2026: revenue n/a, net income −$189M, EPS −$0.24
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$219M, EPS −$0.28
- Quarter ended Sep 30, 2025: revenue n/a, net income −$232M, EPS −$0.31
- Quarter ended Jun 30, 2025: revenue n/a, net income −$566M, EPS −$0.76
- Quarter ended Mar 31, 2025: revenue n/a, net income −$62.9M, EPS −$0.09
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$61.2M, EPS −$0.08
- Quarter ended Sep 30, 2024: revenue $0, net income −$56.3M, EPS −$0.08
- Quarter ended Jun 30, 2024: revenue n/a, net income −$60.4M, EPS −$0.09
- Quarter ended Mar 31, 2024: revenue n/a, net income −$43.5M, EPS −$0.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$36.6M, EPS $0.49
- Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$21.3M, EPS −$0.03
- Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$14.7M, EPS −$0.02
- Quarter ended Mar 31, 2023: revenue $0 (down 100.0% year over year), net income −$542M, EPS −$1.43
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0 (down 100.0% year over year), net income −$19.2M, EPS −$0.04
- Quarter ended Sep 30, 2022: revenue $220K (down 83.2% year over year), net income −$21.4M, EPS −$0.10
- Quarter ended Jun 30, 2022: revenue $235K (up 312.3% year over year), net income −$16.8M, EPS −$0.12
- Quarter ended Mar 31, 2022: revenue $250K (up 30.2% year over year), net income −$21.4M, EPS −$0.15
- Quarter ended Dec 31, 2021 (from the annual report): revenue $251K, net income −$27.1M, EPS $0.01
- Quarter ended Sep 30, 2021: revenue $1.31M, net income −$19.6M, EPS −$0.20
SMMT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$323M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$142M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$76.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$41.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$72.6M, share buybacks n/a
SMMT balance sheet
- Jun 30, 2026: cash $419M, total assets $752M, total liabilities $122M, shareholders' equity $630M
- Mar 31, 2026: cash $107M, total assets $648M, total liabilities $102M, shareholders' equity $546M
- Dec 31, 2025: cash $225M, total assets $751M, total liabilities $92.3M, shareholders' equity $659M
- Sep 30, 2025: cash $239M, total assets $262M, total liabilities $69.5M, shareholders' equity $192M
- Jun 30, 2025: cash $298M, total assets $324M, total liabilities $64.6M, shareholders' equity $259M
- Mar 31, 2025: cash $212M, total assets $384M, total liabilities $39.5M, shareholders' equity $344M
- Dec 31, 2024: cash $105M, total assets $436M, total liabilities $46.8M, shareholders' equity $389M
- Sep 30, 2024: cash $93.8M, total assets $503M, total liabilities $64.9M, shareholders' equity $438M
Is SMMT profitable?
No. Summit Therapeutics Inc lost $856M over the last four quarters.
What is SMMT's EPS?
Diluted earnings per share over the last four quarters were −$1.11; −$0.28 in the latest quarter.